药物警戒中不良事件随访何时能提升药物与疫苗安全性认知:全球专家视角
本研究采用Delphi方法系统收集专家共识,识别不良事件随访在药物警戒中增加价值的场景。专家认为随访在支持因果评估、加强信号检测与监测、支持风险管理与公共卫生行动时有价值,而对已明确标注事件、无法联系报告者或额外数据不太可能改变获益-风险时价值存疑或无价值。
要点
- 随访在解决临床不确定性时提升安全性认知,否则效率低。
- 优先随访支持因果评估、信号检测与风险管理的病例。
- 对已明确标注事件、无法联系报告者等场景可降低随访优先级。
核心结论
- 专家共识认为不良事件随访在解决临床不确定性时能提升药物与疫苗安全性认知,而不考虑影响的随访则效率低下。
研究设计与样本
- 采用基于Delphi的方法系统收集专家对不良事件报告随访场景的共识,数据在十次访谈后达到饱和。
主要发现
- 专家识别出随访在药物警戒中增加价值的三个主要场景:支持因果评估、加强信号检测与监测、支持风险管理与公共卫生行动。
- 专家认为对已明确标注事件、报告者无法联系或未同意进一步联系、以及额外数据不太可能改变获益-风险的场景,随访价值存疑或无价值。
临床怎么用
- 支持转向比例适当、目的驱动的随访策略,包括优先排序和降低优先级的标准,以一致高效地利用资源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION AND OBJECTIVE: Adverse events (AEs) reported with medicines and vaccines form the foundation of pharmacovigilance (PV), enabling the detection, assessment, and prevention of drug-related risks. Initial AE reports often lack relevant clinical detail, limiting their utility. Follow-up is used to obtain additional information but is resource-intensive. Spontaneous reporting systems receive large volumes of reports and follow-up yields additional information in only a proportion of cases. Given these volumes and variable yield, it is important to define when follow-up is most likely to add value and when it is likely to be low-yield or futile. This study aimed to identify scenarios where follow-up on AEs meaningfully improves the understanding of medicine and vaccine safety, and to delineate circumstances when it may be less beneficial or futile. METHODS: A Delphi based methodology was used to systematically gather expert consensus on scenarios in which follow-up of AE reports enhances the understanding of medicine and vaccine safety. RESULTS: Data saturation was achieved after ten interviews. Panel members identified three primary scenarios in which follow-up adds value in PV: supporting causality assessment, strengthening signal detection and monitoring, and informing risk management and public health actions. They saw questionable or no value in follow up of well-characterised labelled events, cases in which the reporter cannot be contacted or did not consent to further contact, and settings where additional data were unlikely to alter benefit-risk. CONCLUSION: This study characterises expert perspectives on when follow-up activities are most likely to provide actionable value. Our results indicate that follow-up improves understanding when it resolves clinical uncertainty, but is inefficient when pursued without regard to impact, supporting a shift to proportionate, purpose-driven follow-up strategies for consistent and efficient use of resources including criteria for prioritisation and de-prioritisation.
引用
- Kara V, Van Hunsel F, Younus M, et al. When does Follow-up on Adverse Events Improve the Understanding of Medicine and Vaccine Safety? Insights from Global Expert Perspectives. Drug Saf. 2026. PMID: 42599564. doi:10.1007/s40264-026-01691-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。